Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4045 in Relapsed or Refractory Multiple Myeloma
NCT07681596Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- Mar 2031
- Countries
- 2
01
Overview
Phase 2, open-label trial of AZD4045 in multiple myeloma (MM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events and Serious Adverse Events at 2 years and Dose-limiting toxicities at 28 days. Started Jul 2026; status: recruiting.
02
Drugs
AZD4045
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07681596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681596.